Prevenar + Meningitec

Prevenar + Meningitec refers to the concomitant administration of two conjugate vaccines: the 7-valent pneumococcal conjugate vaccine (Prevenar) and the meningococcal group C conjugate vaccine (Meningitec). Originally developed by Wyeth (now a subsidiary of Pfizer), both vaccines utilize the CRM197 (a non-toxic mutant of diphtheria toxin) carrier protein to convert T-independent polysaccharide antigens into T-dependent antigens, thereby inducing a robust immune response and immunological memory in infants and young children. Prevenar targets seven serotypes of *Streptococcus pneumoniae* (4, 6B, 9V, 14, 18C, 19F, and 23F) responsible for invasive pneumococcal disease, while Meningitec provides protection against *Neisseria meningitidis* serogroup C, a major cause of bacterial meningitis. Clinical studies, including Phase 4 trials, have evaluated the safety and immunogenicity of administering these vaccines simultaneously at different injection sites to streamline pediatric vaccination schedules.

Brand names

PrevenarMeningitec

Other names

PCV7 + MenC-CRMPneumococcal 7-valent conjugate vaccine + Meningococcal group C conjugate vaccine